Retrophin’s New Strategy Gets A Boost, And A Voucher, Thanks To Cholbam
This article was originally published in The Pink Sheet Daily
Executive Summary
The rare disease company, in the midst of a transition after losing its high-profile CEO last year, takes a step forward with the FDA approval of Cholbam for bile acid synthesis disorders. The company also gained a valuable priority review voucher, which it could sell.